Talk:Q264118
Jump to navigation
Jump to search
Autodescription — acute myeloid leukemia (Q264118)
description: myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells
- Useful links:
- View it! – Images depicting the item on Commons
- Report on constraint conformation of “acute myeloid leukemia” claims and statements. Constraints report for items data
For help about classification, see Wikidata:Classification.
- Parent classes (classes of items which contain this one item)
- acute myeloid leukemia (Q264118)
- acute leukemia (Q976388)
- myeloid leukemia (Q11688946)
- →(@) leukemia (Q29496)
- hematologic cancer (Q18975047) (#)→
- myeloproliferative disorders (Q1898104)
- →(#) hematologic cancer (Q18975047)
- bone marrow disease (Q18556569)
- connective tissue neoplasm (Q3542012)
- →(∇) tumor of hematopoietic and lymphoid tissues (Q2509220)
- disease (Q12136) (●)→
- disease (Q12136) (●)→
- disease (Q12136) (●)→
- →(@) leukemia (Q29496)
- →(●) disease (Q12136)
- acute myeloid leukemia (Q264118)
- Subclasses (classes which contain special kinds of items of this class)
- ⟨
acute myeloid leukemia⟩ on wikidata tree visualisation (external tool)(depth=1) - Generic queries for classes
- See also
- This documentation is generated using
{{Item documentation}}.
Drugs extracted from FAERS[edit]
Hi, I'm contributing on wiki-fr. I would like to point out that the FDA drug FAERS is not a reliable source about the approved and licensed uses of drugs as its primary aim is pharmacovigilance. Thus, reported indications do not necessarily correspond to mainstream indications. To finger out relevant drugs used for treating AML please refer to the labels you can find on FDA website, EMA, MHRA or whatever national administration. Large, phase III clinical trials publications or pre-approval documents might also be helpful. I will remove some irrelevant drugs. Exretic (talk) 12:52, 17 March 2020 (UTC)